$1.8 Billion.
Two Employees.
Medvi · GLP-1s · $1.8B projected · Two employees · FDA warning already on file
Medvi sells compounded GLP-1 weight-loss injections for $299 a month, when pharmacies charge $1,300+. That pricing gap drove $401 million in their first year. For 2026, they're projecting $1.8 billion -- with two employees. The New York Times profiled it as the AI success story of the decade. Sam Altman's prediction of the one-person billion-dollar company had apparently come true.
One viral tweet. One NYT profile. One accepted truth.
A thread on X became a New York Times feature became the definitive AI success story of the decade. Each retelling amplified the last. By the time the story had done its job -- raised the profile, set the frame, validated the thesis -- checking it felt almost beside the point. The writer had spent five to six years studying how stories move online. This is the pattern they kept seeing. And it is not unique to Medvi.
The FDA sent them
a warning letter.
Misbranding violations. Customer reviews already showing bait-and-switch prescriptions. Facebook profiles of fake doctors advertising Medvi. Real physicians publicly asking to be removed from a platform they had never joined.
"I'm not saying Medvi is a scam. I genuinely don't know enough to say that. What I am saying is: the narrative moved faster than the diligence."
-- @aaditsh
"Solo" doesn't mean what people think it means in 2026.
This isn't an AI company that hit $1 billion. It's a medical business that used AI. The entire operation runs on OpenLoop Health, an infrastructure startup out of Iowa that quietly powers dozens of telehealth companies. Nobody is really saying that. The "one person" story is technically true and categorically misleading at the same time.
But the arbitrage
was real.
This is a real pricing gap in a drug category genuinely transforming healthcare. The underlying model has logic. That is what makes this case study interesting -- and what makes the narrative so powerful. The best stories have something real at their centre.
"The story everyone should be studying isn't the company. It's how fast the story moved before anyone checked."
-- @aaditsh
Narrative is probably the most powerful tool in business right now.
It raises your round. It attracts your talent. It sets your valuation. And when it gets ahead of reality, it becomes the thing that takes you down. This isn't about Medvi being good or bad. It's about understanding what narrative actually does -- and building accordingly.
The gap between narrative and reality is not a bug. It's a window. The question is whether you're managing it -- or it's managing you.
-- Mike Litman / Mike's interpretation
"In my little group chat with my tech CEO friends, there's this betting pool for the first year that there is a one-person billion-dollar company. Which would have been unimaginable without AI and now will happen."
-- Sam Altman, interview with Alexis Ohanian, February 2024
Medvi had two employees and a $1.8B projection. Altman's dream -- but built on narrative, not product. The question isn't whether the one-person billion-dollar company is possible. It's whether the billion is real.
MIKE'S INTERPRETATION